Owlet Earnings Call Transcripts
Fiscal Year 2026
-
Q1 revenue grew 6.4% year-over-year to $22.5M, with strong subscription momentum and gross margin expansion. 2026 guidance was revised to prioritize profitability, raising adjusted EBITDA outlook while lowering revenue targets due to a focus on core markets and operational efficiency.
Fiscal Year 2025
-
Record 2025 results with 35% revenue growth, expanding subscriptions, and strong international momentum. 2026 guidance projects 19–23% revenue growth, margin stability, and continued investment in AI and telehealth, with upside from new markets and services.
-
Q3 2025 set records in revenue, profit, and market share, driven by new product launches, international expansion, and regulatory milestones. Raised 2025 guidance reflects strong momentum, despite tariff and macroeconomic headwinds.
-
Q2 2025 saw 26% revenue growth, record gross margins, and continued adjusted EBITDA profitability. Full-year guidance was raised despite tariff headwinds, with strong domestic and subscription growth, and a major warrant exchange simplifying capital structure.
-
Q1 2025 saw 43% revenue growth, record gross margins, and break-even adjusted EBITDA, driven by strong Dream Sock sales, rapid Owlet360 subscription adoption, and new healthcare partnerships. Full-year guidance was raised despite tariff headwinds.
-
Wearable baby health monitors are driving strong retail and international growth, with over 500,000 devices in use and a new subscription service gaining traction. FDA-cleared BabySat is expanding through medical channels, while margins are set to rise as high-value services scale.
Fiscal Year 2024
-
2024 saw record revenue, margin expansion, and the launch of the Owlet 360 subscription, with strong U.S. and international growth. 2025 guidance targets $88–$92 million revenue and higher margins, with profitability expected. Early adoption of new services and medical endorsements signal continued momentum.
-
Q3 2024 saw 141% revenue growth to $22.1M, record gross margin of 52.2%, and positive Adjusted EBITDA, driven by Dream Sock sales and international expansion. BabySat gained traction in medical channels, and a new subscription service showed strong early engagement.
-
Q2 2024 saw 58% revenue growth, 50% gross margin, and positive Adjusted EBITDA, driven by strong U.S. and international demand, new product launches, and operational efficiencies. Guidance calls for continued revenue and margin growth, with BabySat and subscription services ramping into 2025.
-
The company is rapidly expanding its infant health monitoring business, leveraging dual FDA clearances for both OTC and prescription products, and driving growth through retail, medical, and international channels. Near-term priorities include doubling adoption, launching a subscription service, and scaling DME partnerships, with gross margins expected to exceed 50% as the product mix evolves.